Synthetic Biologics to Present at the 2014 BIO CEO & Investor Conference - Action News 5 - Memphis, Tennessee

Synthetic Biologics to Present at the 2014 BIO CEO & Investor Conference

  • HealthMore>>

  • People seek out health info when famous person dies

    People seek out health info when famous person dies

    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
  • A little wine might help kidneys stay healthy

    A little wine might help kidneys stay healthy

    An occasional glass of wine might help keep your kidneys healthy, new research suggests.More >>
    An occasional glass of wine might help keep your kidneys healthy, new research suggests.More >>
  • Mental illness not a driving force behind crime

    Mental illness not a driving force behind crime

    TUESDAY, April 22, 2014 (HealthDay News) -- Less than 10 percent of crimes committed by mentally ill people are directly linked to the symptoms of their disorders, a new study shows. "When we hear about crimes committed by people with mental illness, they tend to be big headline-making crimes, so they get stuck in people's heads," said study author Jillian Peterson, a psychology professor at Normandale Community College in Bloomington, Minn. "The vast majority of people with mental illness a...More >>
    TUESDAY, April 22, 2014 (HealthDay News) -- Less than 10 percent of crimes committed by mentally ill people are directly linked to the symptoms of their disorders, a new study shows. "When we hear about crimes committed by people with mental illness, they tend to be big headline-making crimes, so they get stuck in people's heads," said study author Jillian Peterson, a psychology professor at Normandale Community College in Bloomington, Minn. "The vast majority of people with mental illness a...More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Synthetic Biologics, Inc.

ROCKVILLE, Md., Feb. 4, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 10, 2014, at 10:00 a.m. (ET) at the Waldorf Astoria (Duke of Windsor room) in New York.

A live webcast of Synthetic Biologics' presentation may be accessed by logging onto the internet at http://www.veracast.com/webcasts/bio/ceoinvestor2014/98124275805.cfm. After the presentation, a replay will be archived and accessible for 30 days at the same website.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of product candidates for serious infectious and other diseases. Synthetic Biologics is developing oral treatments targeting archaea, a non-bacterial intestinal form of life increasingly associated with chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of C. diff infection, a series of monoclonal antibodies (mAbs) for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of IBS. In addition, the Company is developing an oral estriol drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS (with results of an ongoing 164 subject, 15 center, two-year, double blind, placebo controlled, Phase II relapsing-remitting MS clinical trial expected to be announced during the first half of 2014). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow